Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$107.24 USD

107.24
2,768,891

-1.46 (-1.34%)

Updated Oct 21, 2024 12:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Neena Mishra headshot

Travel ETFs Flying High on Vaccine Optimism

Travel stocks will benefit from a return to normalcy

Stock Market News for Mar 3, 2021

U.S. markets ended sharply lower on Tuesday led by selloff in tech stocks, a day after recording strong gains, as investors waited for Congress to approve another round of coronavirus relief package.

Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply

Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.

Wall Street Starts a Fresh Week at Record Highs

Wall Street Starts a Fresh Week at Record Highs

Mark Vickery headshot

Merck to Assist J&J Vaccine; Target Beats in Q4

Merck will assist in the manufacture of J&J's just-released Covid-19 vaccine. Specific details are still forthcoming.

Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

Kinjel Shah headshot

Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).

Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue

Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day

Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day

Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study

Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.

Is a Beat in Store for Moderna (MRNA) This Earnings Season?

Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.

Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.

AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes

AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.

Sheraz Mian headshot

Top Research Reports for JPMorgan, Merck & NextEra

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Merck (MRK), and NextEra (NEE).

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.

Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.

Sweta Killa headshot

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Why Merck (MRK) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates

Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.

Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised

Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.